Key Highlights


Shares in Biome Australia (ASX: BIO) have been among the more actively watched small-cap healthcare names heading into the second half of 2026.
On 1 July, the day the company flagged record full-year sales, the stock rose roughly 17% to about A$0.31, according to Business News Australia.
At that level Biome carried a market capitalisation of roughly A$57.6 million.
In May 2025 it added Activated Therapeutics, a practitioner-only range targeting areas such as perimenopause, gastrointestinal repair, acid reflux and weight management, broadening its reach beyond the pharmacy shelf into the healthcare-professional channel.

The Melbourne probiotics group has posted record full-year sales and turned profitable, but a move to onshore manufacturing and an unproven clinical trial will test whether the momentum holds.

Company Overview

Biome Australia is a Melbourne-based complementary medicine company built around live-bacteria, or probiotic, products. Its flagship brand, Activated Probiotics, is sold primarily through community pharmacy, where the company describes it as the number-one probiotic brand by revenue — and number two once Chemist Warehouse is included. In May 2025 it added Activated Therapeutics, a practitioner-only range targeting areas such as perimenopause, gastrointestinal repair, acid reflux and weight management, broadening its reach beyond the pharmacy shelf into the healthcare-professional channel.

Recent Developments

The most consequential recent announcement was strategic rather than financial. On 3 June 2026, Biome signed a binding commercial manufacturing agreement with Specialty Probiotics Australia to transition Activated Probiotics production onshore, with the first commercial batch targeted for September 2026. The company said the deal requires no upfront capital expenditure and, over roughly 18 months, is expected to lift gross margins from about 61% toward 65% or more — a forward-looking target that depends on execution. Biome framed the move as “Phase One” of a…

Financial and Operational Snapshot

For its half-year ended 31 December 2025, Biome reported revenue of $12.40 million, up about 40% on the prior corresponding period. Gross margin was 61.1%, and the company posted EBITDA of $1.47 million excluding share-based payments (an underlying $0.81 million), marking what it described as its eighth consecutive quarter of positive EBITDA. Net profit after tax came in at $1.18 million, up 172%, while cash receipts from customers — a distinct measure from statutory revenue — rose 62% to $13.35 million. It is worth noting…

What May Be Watched Next

The bull case rests on continued pharmacy penetration, the higher-margin practitioner channel, international expansion into Canada, Ireland, the United Kingdom and New Zealand, and the promised margin uplift from local manufacturing. Chief executive Blair Vega Norfolk struck a confident note on the FY26 update, saying the company had “spent two years building for this, and FY27 is set to be our biggest year yet for scale” — a forward-looking statement, not a result.

What does Biome Australia (ASX do?

Biome Australia is a Melbourne-based complementary medicine company built around live-bacteria, or probiotic, products. Its flagship brand, Activated Probiotics, is sold primarily through community pharmacy, where the company describes it as the number-one probiotic brand…

What is the latest development?

The most consequential recent announcement was strategic rather than financial. On 3 June 2026, Biome signed a binding commercial manufacturing agreement with Specialty Probiotics Australia to transition Activated Probiotics production onshore, with the first commercial…

What financial or operational point stands out?

For its half-year ended 31 December 2025, Biome reported revenue of $12.40 million, up about 40% on the prior corresponding period. Gross margin was 61.1%, and the company posted EBITDA of $1.47 million excluding share-based…

What may be watched next?

The bull case rests on continued pharmacy penetration, the higher-margin practitioner channel, international expansion into Canada, Ireland, the United Kingdom and New Zealand, and the promised margin uplift from local manufacturing. Chief executive Blair Vega…